Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma

@article{Mishima2013MolecularAO,
  title={Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma},
  author={Yuji Mishima and Jens G. Lohr and Yu-Tzu Tai and Ludmila M. Flores and Yosra Aljawai and Jacob P. Laubach and Paul G. Richardson and Aldo M. Roccaro and Kenneth C. Anderson and Nikhil C. Munshi and Irene M. Ghobrial},
  journal={Blood},
  year={2013},
  volume={122},
  pages={533-533}
}
Background Clonal evolution involves simultaneous evolution of multiple co-existant subclones. Recent studies have suggested that clonal heterogeneity is critical during the progression of Multiple Myeloma (MM). Circulating tumor cells (CTCs) have been identified in many patients with solid tumors and hematological malignancies. Recent studies have suggested that CTCs can be identified in patients with Multiple Myeloma. The aims of this study were to identify the phenotypic characteristics of… 
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
TLDR
The presence of clonal circulating plasma cells (cPCs) remains a marker of high‐risk disease in newly diagnosed multiple myeloma patients and the role of these findings in developing a risk‐adapted treatment approach in MM patients with actively relapsing disease is needed.
Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
TLDR
A historical excursus is presented on the concepts of clonal heterogeneity and clonal evolution in multiple myeloma with a special emphasis on their role in the progression from MGUS to MM; the contribution of the microenvironment; and the clinical implications in terms of resistance to treatment and disease relapse/recurrence.
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
TLDR
Flow cytometry to quantify cPCs is a valuable test for risk stratifying newly diagnosed multiple myeloma patients in the era of novel agents, but future studies are needed to determine its role in developing a risk-adapted treatment approach.